
Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study
Author(s) -
Abulseoud Osama A.,
Gitlin Michael,
Altshuler Lori,
Frye Mark A.
Publication year - 2013
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.109
Subject(s) - citalopram , medicine , baseline (sea) , thyroid , biology , antidepressant , hippocampus , fishery
The lack of reliable outcome predictors and the delayed onset of therapeutic response to antidepressants are among the clinical challenges in the treatment of depression. Identifying clinical correlates associated with antidepressant response would reduce symptom severity and morbidity for patients with depression. Twenty‐three subjects with major depression were treated with citalopram 20 mg/day in a 6‐week open trial and were also simultaneously randomized to either adjunctive triiodothyronine (T3) 25 μ g BID ( n = 7), pindolol 5 mg BID ( n = 8), or placebo ( n = 8). Baseline thyroid‐stimulating hormone ( TSH ), FT 4, FT 3, and TT 3 were measured for potential relationships to treatment response across groups. In males only, there was a significant inverse correlation between baseline free T 4 and time to response ( r = −0.7, P = 0.034). In both males and females across all treatment conditions, as measured by Kaplan–Meier ( K – M ) maintenance failure time, baseline TSH below the mean (1.5 ng/dL) was associated with a shorter time to response (50% reduction in Montgomery and Asberg Depression Rating Scale [ MADRS ] score) (χ 2 = 4.53, df = 1, P = 0.03). Patients with baseline TSH above the mean were less likely to reach full remission ( MADRS ≤ 7) (χ 2 = 4.38, df = 1, P = 0.03). No significant differences between groups emerged in the mean response time. Baseline thyroid function, as measured by serum free T 4 and TSH , may predict a patient's response time to antidepressant treatment with citalopram.